In the latest session, Exact Sciences Corp. (NASDAQ: EXAS) closed at $56.90 down -1.06% from its previous closing price of $57.51. In other words, the price has decreased by -$0.61 from its previous closing price. On the day, 3123393 shares were traded.
Ratios:
For a deeper understanding of Exact Sciences Corp.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 323.49. For the most recent quarter (mrq), Quick Ratio is recorded 2.07 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on December 13, 2023, with a $95 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 23 when Condella Sarah sold 1,021 shares for $59.72 per share. The transaction valued at 60,974 led to the insider holds 71,658 shares of the business.
Conroy Kevin T sold 11,565 shares of EXAS for $691,356 on Feb 22. The President and CEO now owns 1,241,429 shares after completing the transaction at $59.78 per share. On Feb 22, another insider, Elliott Jeffrey Thomas, who serves as the Chief Financial Officer of the company, sold 1,351 shares for $59.78 each. As a result, the insider received 80,763 and left with 5,063 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.13 while its Price-to-Book (P/B) ratio in mrq is 3.28. Its current Enterprise Value per Revenue stands at 4.84.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $100.77, while it has fallen to a 52-week low of $56.85. The 50-Day Moving Average of the stock is 66.21, while the 200-Day Moving Average is calculated to be 75.31.
Shares Statistics:
For the past three months, EXAS has traded an average of 1.87M shares per day and 2.51M over the past ten days. A total of 181.36M shares are outstanding, with a floating share count of 179.73M. Insiders hold about 0.99% of the company’s shares, while institutions hold 89.92% stake in the company. Shares short for EXAS as of Jan 31, 2024 were 7.29M with a Short Ratio of 3.91, compared to 7.5M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.03% and a Short% of Float of 4.07%.
Earnings Estimates
There are 16 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.63, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.09 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.31 and -$1.29 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is $0.01, with 18 analysts recommending between $0.81 and -$0.64.
Revenue Estimates
A total of 20 analysts believe the company’s revenue will be $630.32M this quarter.It ranges from a high estimate of $682M to a low estimate of $619.99M. As of the current estimate, Exact Sciences Corp.’s year-ago sales were $602.45M, an estimated increase of 4.60% from the year-ago figure. For the next quarter, 20 analysts are estimating revenue of $700.87M, an increase of 12.70% over than the figure of $4.60% in the same quarter last year. There is a high estimate of $721.08M for the next quarter, whereas the lowest estimate is $687.31M.
A total of 23 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $2.87B, while the lowest revenue estimate was $2.82B, resulting in an average revenue estimate of $2.83B. In the same quarter a year ago, actual revenue was $2.5B, up 13.40% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $3.23B in the next fiscal year. The high estimate is $3.3B and the low estimate is $3.17B. The average revenue growth estimate for next year is up 13.90% from the average revenue estimate for this year.
